• Skip to main content
  • Skip to primary sidebar
Pediatric Pulmonology: The Remaining Barriers to Normalcy in Cystic Fibrosis

The Remaining Barriers to Normalcy in Cystic Fibrosis

  • Issues
  • Resources
  • About
  • Contact
  • Search

Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre- and posttransplant

By Zain Raza MD; Bianca N. Islam MD, PhD; Christine Y. Hachem MD; Linda C. Cummings MD, MS

Advances in treatment for cystic fibrosis (CF), including cystic fibrosis transmembrane conductor regulator (CFTR) modulators, have ushered in an era where patients with CF have much longer life expectancies. This shift in life expectancy demands increased attention to diseases of aging in patients with CF. A notable complication of CF is early-onset colorectal cancer (CRC), which is especially prevalent in patients with severe mutations and after transplant. CFTR acts as a tumor suppressor gene based on knockout models. Lack of CFTR expression promotes carcinogenic processes such as intestinal inflammation and deleterious gut microbiome changes. The consensus Cystic Fibrosis Foundation recommendations advocate treating this population as a high-risk group, using a colonoscopy-only screening strategy starting at age 40 in patients without transplant and at age 30 after transplant. Screening should be considered every 5 years if negative and every 3 years or sooner for patients with adenomatous polyps. Future research will determine the role of noninvasive CRC screening tools in this population, as well as the effects of CFTR modulators on the risk of developing CRC.

Read the Full Article  

Journal Issue: Remaining Barriers to Normalcy in Cystic Fibrosis: Advances in Gastroenterology, Hepatology, and Nutrition

Primary Sidebar

PP Cover - September 2024

Pediatric Pulmonology

Remaining Barriers to Normalcy in Cystic Fibrosis: Advances in Gastroenterology, Hepatology, and Nutrition

September 2024 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VII

February 2022 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VI

February 2021 · View Articles

List all issues »

Most Viewed Articles

  • Rapid therapeutic advances in CFTR modulator science

  • Reevaluating approaches to cystic fibrosis pulmonary exacerbations

  • Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

  • Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

  • Inflammation in cystic fibrosis: An update

Quiz and Survey

Test your knowledge and help shape future editions of "The Remaining Barriers to Normalcy." Participate in our Quiz and Survey »

This website is made possible by an educational grant from Vertex Pharmaceuticals Incorporated.

Vertex

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2018-2025 John Wiley & Sons, Inc. All Rights Reserved.
The content on this site is intended for health professionals.
Wiley